Kymera Therapeutics (NASDAQ:KYMR) Trading Down 7.7% Following Insider Selling

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s share price dropped 7.7% during trading on Friday after an insider sold shares in the company. The stock traded as low as $107.74 and last traded at $107.4440. Approximately 1,077,630 shares traded hands during trading, an increase of 48% from the average daily volume of 728,169 shares. The stock had previously closed at $116.46.

Specifically, Director Bruce Booth sold 285,684 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $121.86, for a total value of $34,813,452.24. Following the sale, the director directly owned 529,718 shares in the company, valued at approximately $64,551,435.48. This represents a 35.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce Booth sold 262,637 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $115.39, for a total value of $30,305,683.43. Following the completion of the transaction, the director directly owned 564,668 shares of the company’s stock, valued at approximately $65,157,040.52. The trade was a 31.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In related news, Director Bruce Booth sold 134,720 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $100.51, for a total transaction of $13,540,707.20. Following the completion of the transaction, the director owned 597,047 shares in the company, valued at $60,009,193.97. This trade represents a 18.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Wall Street Analyst Weigh In

A number of analysts have weighed in on KYMR shares. Brookline Capital Markets reiterated a “buy” rating on shares of Kymera Therapeutics in a research report on Monday, June 8th. Morgan Stanley restated an “overweight” rating and issued a $119.00 target price on shares of Kymera Therapeutics in a research note on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. Citigroup increased their target price on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Canaccord Genuity Group lifted their price target on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.18.

Key Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Enrollment in the BROADEN2 Phase 2b trial finished early, accelerating the path to topline data and improving sentiment around Kymera’s lead asset. Article: Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
• Positive Sentiment: BTIG reaffirmed a Buy rating and highlighted further upside with a $134 target price. Article: Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
• Neutral Sentiment: The company appointed Felix J. Baker, Ph.D. as chairman of the board, a governance update that may support the long term but is less likely to move the stock immediately. Article: Kymera Therapeutics Appoints Felix J. Baker, Ph.D.
• Negative Sentiment: Insider selling by director Bruce Booth and insider Noah Goodman may temper enthusiasm somewhat, although the trades were disclosed and Booth’s sales were made under a pre-arranged 10b5-1 plan. Article: Insider transaction filing

Kymera Therapeutics Stock Performance

The company’s 50-day moving average is $84.43 and its 200-day moving average is $82.12. The firm has a market cap of $8.91 billion, a price-to-earnings ratio of -30.39 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same period in the previous year, the firm posted ($0.82) earnings per share. The company’s revenue was up 55.5% on a year-over-year basis. On average, analysts predict that Kymera Therapeutics, Inc. will post -3.25 EPS for the current year.

Institutional Trading of Kymera Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of KYMR. Smartleaf Asset Management LLC raised its position in Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares during the last quarter. Larson Financial Group LLC raised its position in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after acquiring an additional 349 shares during the last quarter. Osaic Holdings Inc. raised its position in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after acquiring an additional 1,083 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Kymera Therapeutics during the fourth quarter valued at $63,000. Finally, Raymond James Financial Inc. bought a new position in Kymera Therapeutics in the second quarter valued at about $73,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.